论文部分内容阅读
目的采用拉米夫定联合阿德福韦酯治疗耐阿德福韦酯乙肝肝硬化,并探讨其临床治疗效果。方法 72例乙肝肝硬化患者随机分为实验组和对照组,每组36例。实验组患者服用阿德福韦酯配合拉米夫定治疗;对照组患者服用恩替卡韦治疗。对比两组疗效。结果 1、2年后两组患者的乙肝e抗原(HBeAg)阴转率、乙肝病毒基因(HBV-DNA)阴转率差异无统计学意义(P>0.05);两组患者ChildPugh评分均明显改善,差异具有统计学意义(P<0.05),两组组间对比差异无统计学意义(P>0.05);两组并发症发生情况差异无统计学意义(P>0.05)。结论长期服用阿德福韦酯联合拉米夫定或用恩替卡韦治疗耐药乙肝肝硬化安全可靠的,但从治疗费用方面考虑,阿德福韦酯联合拉米夫定相对比较经济。
Objective To treat adefovir dipivoxil-resistant hepatitis B cirrhosis with lamivudine combined with adefovir dipivoxil and to explore its clinical effect. Methods 72 cases of hepatitis B cirrhosis patients were randomly divided into experimental group and control group, 36 cases in each group. Patients in the experimental group were treated with adefovir dipivoxil plus lamivudine; patients in the control group were treated with entecavir. Compare two groups curative effect. Results After 1 and 2 years, there was no significant difference in the negative conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of HBV-DNA between the two groups (P> 0.05). The ChildPugh scores of both groups were significantly improved (P <0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference in the complication between the two groups (P> 0.05). Conclusion Long-term use of adefovir dipivoxil combined with lamivudine or entecavir treatment of resistant hepatitis B cirrhosis safe and reliable, but from the treatment costs, adefovir dipivoxil combined lamivudine is relatively economical.